Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-04-26 Annual Report
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech Holding ASA - Annual Report 2023
Annual Report Classification · 100% confidence The document is explicitly titled 'ANNUAL REPORT' and contains standard sections such as 'Board of Directors report', 'Financial statements', and 'Auditors report'. It covers the company's activities, business strategy, and operational performance for the fiscal year 2023. It meets the criteria for a comprehensive annual report. FY 2023
2024-04-26 English
PCI Biotech Holding ASA - Annual Report 2023
Report Publication Announcement Classification · 100% confidence The document explicitly states 'PCI Biotech Holding ASA - Annual Report 2023' in the title and body. However, the document length is very short (734 characters) and it primarily serves to announce that the 'Annual Report 2023' is 'attached' and available on the website. According to Rule #2 (The 'MENU VS MEAL' Rule), a short announcement stating a report is attached or published should be classified as a Report Publication Announcement (RPA), rather than the full report itself (10-K).
2024-04-26 English
PCI Biotech second half 2023 interim results
Investor Presentation Classification · 95% confidence The document is a presentation titled 'PCI Biotech - Preliminary full year 2023 Interim Report' dated February 14, 2024. It contains operational reviews, key financial highlights, and outlook information. While it is titled an 'Interim Report', the format is clearly a slide deck presentation used for investor communication, which aligns with the definition of an Investor Presentation (IP). It provides a summary of financial performance and strategic goals rather than being the formal, comprehensive financial report document. FY 2023
2024-02-14 English
PCI Biotech second half 2023 interim results
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 PRELIMINARY INTERIM REPORT' and contains comprehensive financial statements (Income Statement, Cash Flow, Balance Sheet) for the half-year (2H) and full-year (FY) periods of 2023. It provides detailed operational reviews, pipeline updates, and financial analysis. It is not an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report. FY 2023
2024-02-14 English
PCI Biotech second half 2023 interim results
Report Publication Announcement Classification · 99% confidence The document explicitly announces the company's "second half 2023 interim results" and states, "Please find enclosed the interim report and presentation." It provides key highlights, operational updates, and corporate commentary for the period, which is characteristic of an Interim/Quarterly Report (IR). However, the document itself is a short announcement (4856 characters) that directs the reader to the actual report and presentation which are 'enclosed' or available elsewhere (NewsWeb/company webpage). According to Rule 2 (The 'MENU VS MEAL' Rule), a short announcement stating that the full report is attached or published elsewhere should be classified as a Report Publication Announcement (RPA). Since this document is announcing the publication of the 'interim report' and presentation, RPA is the most appropriate classification, even though the content relates to interim results.
2024-02-14 English
PCI Biotech: Invitation to second half interim 2023 results presentation
Report Publication Announcement Classification · 98% confidence The document is titled "PCI Biotech: Invitation to second half interim 2023 results presentation" and explicitly states that the company invites stakeholders to a webcast presentation of its "second half 2023 interim report." It mentions that the interim report and presentation will be made available on a specific date. This structure—announcing the release and presentation of a periodic financial report (Interim Report)—fits the definition of a Report Publication Announcement (RPA). The document itself is short (2866 chars) and serves as an invitation/notice rather than the comprehensive report (IR) or the earnings highlights (ER).
2024-02-12 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.